

Magdeburg, January 30, 2024

neotiv is part of a multinational consortium to shape the future of healthcare for Alzheimer's Disease

Magdeburg, January 30, 2024 — neotiv is proud to be part of AD-RIDDLE, a new interdisciplinary initiative to revolutionize the way Alzheimer's disease is detected, diagnosed, prevented, and treated. Developed by a consortium of 24 partners, the Real-World Implementation, Deployment, and Validation of Early Detection Tools and Lifestyle Enhancement (AD-RIDDLE) project will offer healthcare providers a toolbox platform of validated resources and tailored interventions to optimize healthcare for Alzheimer's disease. The AD-RIDDLE platform allows for flexible adaptation and application in diverse settings, from memory clinics to primary care, to the broader population outside of healthcare systems. A real-world testing study will be conducted in these settings across 6 European countries and will provide extensive evidence to support implementation of diagnostic tools, treatments, and lifestyle interventions, to match individuals with the right interventions at the right time, enabling people to better understand what they can do to reduce risk and prevent cognitive decline.

Funded by the Innovative Health Initiative (IHI), an EU public-private partnership funding health research and innovation, AD-RIDDLE brings together a unique, interdisciplinary collaboration of academic and healthcare providers, pharmaceutical and diagnostic companies, regulatory bodies, and patient advocacy organizations.

neotiv will provide the consortium with its digital platform for remote and unsupervised digital cognitive assessment. The neotiv digital platform is designed for the early detection of cognitive impairment in AD and for monitoring subtle cognitive change over time. It has been developed for remote and unsupervised use in clinical trials and healthcare settings. neotiv will support the AD-RIDDLE platform's central aim of enabling screening and early diagnosis in combination with blood-based biomarkers. neotiv will provide the consortium with the neotivTrials app. The CE marked version of this app, neotivCare is a medical product in German healthcare already. neotiv will be able to contribute insights from its activities in the German healthcare system and experience in implementing novel digital cognitive assessment tools in healthcare and making them accessible to primary care physicians, specialists and patients.

neotiv is deeply rooted in Alzheimer's and brain research. Bringing clinically impactful advances from basic and clinical research into safe, easy to use and extensively validated products is the key mission of neotiv. Having established certified solutions in healthcare, neotiv aims to further improve diagnostics by linking its digital solution with fluid biomarkers and extending the patient journey to an early entry point with effective screening methods.

"With disease-modifying treatments on the horizon, it is critical to enable healthcare systems in and outside Europe to identify patients who can benefit from these new treatments and offer prevention strategies - hence the need to redesign today's patient journey," says Professor Dr. Emrah Düzel, co-founder and Chief Medical Officer of neotiv. Dr. David Berron, also co-founder of neotiv and Chief Scientific Officer, adds: "One of the goals of this consortium is to add digital cognitive assessments to the patient journey of the future - here they can help in the early detection of Alzheimer's disease in combination with novel blood-based biomarkers, prediction of future cognitive decline and monitoring of cognitive changes."

Data from the initiative will be hosted in a GDPR-compliant manner on the European Platform for Neurodegenerative Diseases (EPND), an IMI2-funded initiative which will make datasets available for additional research and discovery, with the goal of facilitating new findings in neurodegenerative disease research.

neotiv is excited to be taking part in AD-RIDDLE and looks forward to jointly improving patient healthcare in Alzheimer's disease.

About neotiv GmbH

neotiv is a German digital health company developing a digital platform for remote and unsupervised cognitive assessments, primarily in neurocognitive disorders. With its healthcare product neotivCare, it is firmly anchored in the German healthcare system. As a scientific spin-off of the Otto-von-Guericke University Magdeburg, Germany, with dense collaborations with international research initiatives, neotiv is dedicated to ongoing innovation and validation of its digital platform. For more information, contact info@neotiv.com or visit neotiv.com/en

About AD-RIDDLE

AD-RIDDLE receives funding under the auspices of the Innovative Health Initiative Joint Undertaking (IHI JU) and UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee. The AD-RIDDLE programme has an initial budget of over €31 million, comprising €12,090,250 from the EU, €16,421,395 from the contributing partners and €2,368,307.25 from UKRI. The budget is distributed across a total of 24 partners:

- Region Stockholm (manages all publicly-financed healthcare in Stockholm County)
- Karolinska Institutet

- FINGERS Brain Health Institute
- University of Gothenburg
- Lund University
- University of Eastern Finland
- Stichting VUmc
- Universiteit Maastricht
- Fundacio BarcelonaBeta Brain Research Center
- SYNAPSE Research Management Partners SL
- Alzheimer Europe
- Alzheimer's Disease International
- Università Degli Studi Di Perugia
- Gates Ventures LLC
- Davos Alzheimer's Collaborative
- Combinostics OY
- Fujirebio Europe NV
- Sanofi
- C2N Diagnostics LLC
- neotiv GmbH
- Cambridge Cognition Limited
- University of Leicester
- Imperial College of Science Technology and Medicine
- National Institute for Health and Care Excellence

For more information, contact info@adriddle.org or visit ad-riddle.org .

About the Innovative Health Initiative

The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA (including Vaccines Europe), EuropaBio, and MedTech Europe. IHI's total budget is €2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation program. The IHI industry partners have committed €1 billion to IHI, and a further €200 million can be committed by other organizations that decide to become Contributing Partners.

Acknowledgement

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No. 101132933. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA (including Vaccines Europe), EuropaBio, MedTechEurope, Gates Ventures, Davos Alzheimer's Collaborative, Combinostics OY, Fujirebio Europe N.V, Cambridge Cognition Ltd., Sanofi, C2N Diagnostics LLC, and neotiv GmbH. The participation of Cambridge Cognition Limited, University of Leicester, Imperial College of Science Technology and Medicine, and the National Institute for Health and Care Excellence (NICE) will be funded by UKRI under the UK government's Horizon Europe funding guarantee.

Disclaimer

Funded by the European Union, the private members, UKRI, and the contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. None of the aforementioned parties can be held responsible for them.

Media Relations

Further information about neotiv can be found at neotiv.com/en/press.

Questions and approvals of articles can be sent to presse@neotiv.com.